文献速递慢阻肺

慢阻肺患者急性加重风险及布地奈德反应预测因素:三项随机试验事后分析

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
PubMed 文献 · Lancet Respir Med · 2018-01-10

该事后分析纳入三项阿斯利康布地奈德-福莫特罗随机对照试验的4528例有急性加重史的COPD患者,以连续变量建模血嗜酸性粒细胞计数。结果显示,单用福莫特罗时急性加重随嗜酸性粒细胞计数非线性增加;嗜酸性粒细胞计数和吸烟史是布地奈德-福莫特罗减少急性加重反应的独立预测因素。

要点

  • 嗜酸性粒细胞计数和吸烟史是布地奈德-福莫特罗减少急性加重反应的独立预测因素。
  • 单用福莫特罗时,急性加重随血嗜酸性粒细胞计数增加呈非线性上升。

核心结论

  • 在接受福莫特罗治疗的COPD患者中,血嗜酸性粒细胞计数可预测急性加重风险及对ICS的临床反应。

研究设计与样本

  • 对三项阿斯利康布地奈德-福莫特罗随机对照试验进行事后分析,纳入有急性加重史且有血嗜酸性粒细胞计数的COPD患者,排除有哮喘史者。
  • 共分析4528例患者,采用负二项回归及样条函数建模连续变量,主要结局为经暴露时间和研究设计校正的年急性加重率。

主要发现

  • 单用福莫特罗时,急性加重随血嗜酸性粒细胞计数增加呈非线性上升。

临床怎么用

  • 对接受福莫特罗治疗且有急性加重史的COPD患者,可参考血嗜酸性粒细胞计数评估ICS减少急性加重的获益可能。

局限性

  • 本文为三项随机试验的事后分析,非预设主要分析。
  • 研究排除有哮喘史者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The peripheral blood eosinophil count might help identify those patients with chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations when taking inhaled corticosteroids (ICS). Previous post-hoc analyses have proposed eosinophil cutoffs that are both arbitrary and limited in evaluating complex interactions of treatment response. We modelled eosinophil count as a continuous variable to determine the characteristics that determine both exacerbation risk and clinical response to ICS in patients with COPD. METHODS: We analysed data from three AstraZeneca randomised controlled trials of budesonide-formoterol in patients with COPD with a history of exacerbations and available blood eosinophil counts. Patients with any history of asthma were excluded. Negative binomial regression analysis was done using splines for modelling of continuous variables to study the primary outcome of annual exacerbation rate adjusted for exposure time and study design. The trials are registered with ClinicalTrials.gov, NCT00206167, NCT00206154, and NCT00419744. FINDINGS: 4528 patients were studied. A non-linear increase in exacerbations occurred with increasing eosinophil count in patients who received formoterol alone. At eosinophil counts of 0·10 × 109 cells per L or more, a significant treatment effect was recorded for exacerbation reduction with budesonide-formoterol compared with formoterol alone (rate ratio 0·75, 95% CI 0·57-0·99; pinteraction=0·015). Interactions were observed between eosinophil count and the treatment effects of budesonide-formoterol over formoterol on St George's Respiratory Questionnaire (pinteraction=0·0043) and pre-bronchodilator FEV1 (linear effect p<0·0001, pinteraction=0·067). Only eosinophil count and smoking history were independent predictors of response to budesonide-formoterol in reducing exacerbations (eosinophil count, pinteraction=0·013; smoking history, pinteraction=0·015). INTERPRETATION: In patients with COPD treated with formoterol, blood eosinophil count predicts exacerbation risk and the clinical response to ICS. FUNDING: AstraZeneca.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018. PMID: 29331313. doi:10.1016/S2213-2600(18)30006-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。